Floxuridine

From Wikipedia, the free encyclopedia

Floxuridine
Systematic (IUPAC) name
5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione
Identifiers
CAS number 50-91-9
ATC code  ?
PubChem 5790
DrugBank APRD00692
Chemical data
Formula C9H11FN2O5 
Mol. mass 246.193 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Floxuridine is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.

Contents

[edit] Pharmacology

Floxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.

[edit] Meachanism of action

Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.

[edit] History

Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to Faulding, which became Mayne Pharma.

[edit] Suppliers

In the US the drug is supplied by Mayne Pharma as well as APP and Bedford.